Insider · CIK 0001742084
Gilmore Neil O'Neill
Files at EDIT (Editas Medicine, Inc.). First filing Dec 5, 2024, latest Sep 4, 2026.
Gilmore Neil O'Neill files SEC Form 4 as CEO and director at EDIT (Editas Medicine, Inc.). Since Dec 5, 2024, Gilmore Neil O'Neill has reported 0 open-market buys worth $0 and 8 open-market sells worth $153k, the latest filed on Sep 4, 2026.
A track record needs three past buys with six months of prices behind them; Gilmore Neil O'Neill has 0, so none is measured yet.
The newest scored trade: sold $16k of EDIT on Sep 3, 2026, filed Sep 4, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $80k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EDIT: Editas Medicine, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Editas Medicine, Inc. | $16k 5,124 shares | -2% | - | |
| 26Weak | Editas Medicine, Inc. | $42k 15,380 shares | -6% | +67% from low-33% from high | |
| 20Weak | Editas Medicine, Inc. | $11k 5,394 shares | -2% | +108% from low-51% from high | |
| 20Weak | Editas Medicine, Inc. | $12k 5,603 shares | -2% | +141% from low-43% from high | |
| 20Weak | Editas Medicine, Inc. | $15k 5,592 shares | -2% | +155% from low-37% from high | |
| 25Weak | Editas Medicine, Inc. | $26k 15,192 shares | -5% | +86% from low-54% from high | |
| 25Weak | Editas Medicine, Inc. | $28k 16,632 shares | -5% | - | |
| 13Weak | Editas Medicine, Inc. | $3,361 1,618 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 31, 2026 | EDIT Editas Medicine, Inc. | 5,100 0.00% of outstanding | $17k | Sep 3, 2026 | $42k |
| May 29, 2026 | EDIT Editas Medicine, Inc. | 15,000 0.02% of outstanding | $46k | Jun 3, 2026 | $11k |
| Feb 27, 2026 | EDIT Editas Medicine, Inc. | 6,000 0.01% of outstanding | $11k | Mar 3, 2026 | $12k |
| Dec 1, 2025 | EDIT Editas Medicine, Inc. | 7,000 0.01% of outstanding | $18k | Dec 3, 2025 | $15k |
| Aug 29, 2025 | EDIT Editas Medicine, Inc. | 7,000 0.01% of outstanding | $19k | Sep 3, 2025 | $26k |
| Jun 2, 2025 | EDIT Editas Medicine, Inc. | 20,000 0.02% of outstanding | $37k | Jun 3, 2025 | $28k |
| Feb 28, 2025 | EDIT Editas Medicine, Inc. | 35,000 0.04% of outstanding | $65k | Mar 3, 2025 | $3,361 |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -5,124 | $3.04 | $16k | 243,189 | 39 d ago |
| Jun 3, 2026 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -15,380 | $2.70 | $42k | 248,313 | Jun 5, 2026 |
| Mar 12, 2026 | EDIT Editas Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative10b5-1 | +1,015,200 | $0.00 | $0 | 1,015,200 | Mar 16, 2026 |
| Mar 3, 2026 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -5,394 | $2.02 | $11k | 263,693 | Mar 4, 2026 |
| Dec 3, 2025 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -5,603 | $2.15 | $12k | 269,087 | Dec 4, 2025 |
| Sep 3, 2025 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -5,592 | $2.60 | $15k | 274,690 | Sep 4, 2025 |
| Jun 3, 2025 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -15,192 | $1.72 | $26k | 280,282 | Jun 4, 2025 |
| Mar 8, 2025 | EDIT Editas Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +828,000 | $0.00 | $0 | 828,000 | Mar 27, 2025 |
| Mar 8, 2025 | EDIT Editas Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 27, 2025 |
| Mar 4, 2025 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -16,632 | $1.71 | $28k | 295,474 | Mar 5, 2025 |
| Dec 3, 2024 | EDIT Editas Medicine, Inc. | SOpen-market sale Common Stock10b5-1 | -1,618 | $2.08 | $3,361 | 312,106 | Dec 5, 2024 |
Questions about Gilmore Neil O'Neill
Answered from the filings on this page, as of the latest one.
Is Gilmore Neil O'Neill buying or selling?
In the last 12 months Gilmore Neil O'Neill reported 0 open-market buys worth $0 and 4 open-market sells worth $80k on SEC Form 4; the latest was sold $16k of EDIT on Sep 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Gilmore Neil O'Neill's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gilmore Neil O'Neill has 0.
Where does Gilmore Neil O'Neill file Form 4?
Gilmore Neil O'Neill has filed Form 4 at EDIT (Editas Medicine, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.